Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Mirabegron, sold under the brand name Myrbetriq among others, is a medication used to treat overactive bladder. Its benefits are similar to antimuscarinic medication such as solifenacin or tolterodine. It is taken by mouth.
The analysis highlights Research, Adverse effects and Overview as prominent areas in the source structure around Mirabegron.
Source areas are shown by the number of related topics found in each part of the analysis. Use smaller areas too: they can reveal specialized angles and content gaps.
Smaller areas are not necessarily less important. They contain fewer connections in this analysis and can be useful for finding specialized angles or coverage gaps.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the complete topic structure, not only the most central items. Less prominent entities and concepts can reveal missing angles, specialized context and useful research gaps. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
The extracted context around Mirabegron shows recurring relationship patterns in the source. For example, Mirabegron → AU: S4 (Prescription only), EU: Rx-only, In general: ℞ (Prescription only), UK: POM (Prescription only), US: ℞-only Another extracted example is Mirabegron → In, It, NDO, United Kingdom. Use these groups to spot repeated connection types before inspecting the individual relationships.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
medication bladder effects overactive include urinary united liver mouth used adrenergic beta-3 side available use states medical cyp2d6 cyp3a4 solifenacin
TTTA extracted 41 structured relationships around Mirabegron. Examples in this analysis include Mirabegron → 3D model (JSmol) → Interactive image and Mirabegron → AHFS/Drugs.com → Monograph. The table shows each extracted connection, where it came from and its confidence.
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Mirabegron | 3D model (JSmol) | Interactive image | 1.00 | infobox |
| Mirabegron | AHFS/Drugs.com | Monograph | 1.00 | infobox |
| Mirabegron | ATC code | G04BD12 (WHO) | 1.00 | infobox |
| Mirabegron | Bioavailability | 29–35% | 1.00 | infobox |
| Mirabegron | CAS Number | 223673-61-8 | 1.00 | infobox |
| Mirabegron | ChEBI | CHEBI:65349 | 1.00 | infobox |
| Mirabegron | ChEMBL | ChEMBL2095212 | 1.00 | infobox |
| Mirabegron | ChemSpider | 8041219 | 1.00 | infobox |
| Mirabegron | CompTox Dashboard (EPA) | DTXSID101021648 | 1.00 | infobox |
| Mirabegron | DrugBank | DB08893 | 1.00 | infobox |
| Mirabegron | ECHA InfoCard | 100.226.392 | 1.00 | infobox |
| Mirabegron | Elimination half-life | 50 hours | 1.00 | infobox |
| Mirabegron | Excretion | Urine (55%), faeces (34%) | 1.00 | infobox |
| Mirabegron | Formula | C21H24N4O2S | 1.00 | infobox |
| Mirabegron | KEGG | D09535 | 1.00 | infobox |
| Mirabegron | Legal status | AU: S4 (Prescription only) | 1.00 | infobox |
| Mirabegron | Legal status | UK: POM (Prescription only) | 1.00 | infobox |
| Mirabegron | Legal status | US: ℞-only | 1.00 | infobox |
| Mirabegron | Legal status | EU: Rx-only | 1.00 | infobox |
| Mirabegron | Legal status | In general: ℞ (Prescription only) | 1.00 | infobox |
| Mirabegron | License data | US DailyMed: Mirabegron | 1.00 | infobox |
| Mirabegron | MedlinePlus | a612038 | 1.00 | infobox |
| Mirabegron | Metabolism | Liver via (direct) glucuronidation, amide hydrolysis, and minimal oxidative metabolism in vivo by CYP2D6 and CYP3A4. Some involvement of butylcholinesterase | 1.00 | infobox |
| Mirabegron | Molar mass | 396.51 g·mol−1 | 1.00 | infobox |
| Mirabegron | Other names | YM-178 | 1.00 | infobox |
| Mirabegron | Pregnancy category | AU: B3 | 1.00 | infobox |
| Mirabegron | Protein binding | 71% | 1.00 | infobox |
| Mirabegron | PubChem CID | 9865528 | 1.00 | infobox |
| Mirabegron | Routes of administration | By mouth | 1.00 | infobox |
| Mirabegron | Trade names | Myrbetriq, Betanis, Betmiga, others | 1.00 | infobox |
The concept neighborhoods around Mirabegron bring nearby vocabulary together. In this analysis, examples include Bladder, Liver and Overactive. Use the clusters to find adjacent concepts and terminology that may deserve separate research.
For Mirabegron, one of the stronger structural bridges in this analysis connects Mirabegron with Adverse effects. Bridges highlight paths between different parts of the map and can reveal research angles that are easy to miss in a flat list.
TTTA analyzes the structure around Mirabegron to surface related topics, entities, relationships, concept neighborhoods and bridge connections. Use the map to explore areas such as Research, Adverse effects & Overview, including less central topics that may reveal useful research gaps. Automatically extracted connections are research leads rather than rewritten encyclopedia content.
Source: Wikipedia — Mirabegron · EN edition · Analysis: TopicsToTalkAbout